Literature DB >> 29293952

Aiming at the appropriate target for the treatment of pulmonary hypertension due to left heart disease.

Nazzareno Galiè1, Alessandra Manes2, Fabio Dardi1, Massimiliano Palazzini1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29293952     DOI： 10.1093/eurheartj/ehx751

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  2 in total

Review 1.  Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.

Authors:  Filippos Triposkiadis; Andrew Xanthopoulos; John Skoularigis; Randall C Starling
Journal:  Heart Fail Rev       Date:  2022-04-18       Impact factor: 4.654

Review 2.  The Biological Bases of Group 2 Pulmonary Hypertension.

Authors:  Ana I Fernández; Raquel Yotti; Ana González-Mansilla; Teresa Mombiela; Enrique Gutiérrez-Ibanes; Candelas Pérez Del Villar; Paula Navas-Tejedor; Christian Chazo; Pablo Martínez-Legazpi; Francisco Fernández-Avilés; Javier Bermejo
Journal:  Int J Mol Sci       Date:  2019-11-23       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.